Dr. Harald Petry - CEO and co-founder
Harald has 20+ years of experience in the field of gene therapy. After his PhD on retroviruses, retroelements and cancer, he worked for 10 years at the German Primate Center on vaccines. During this time, he worked on a Polyomavirus-based gene delivery system which was transferred to Jenapharm GmbH for further development.
Harald joined Jenapharm GmbH in 2000. In 2002 he joined Berlex Biosciences (US) as Project Leader. In 2007, he became the Director of Research at Amsterdam Molecular Therapeutics (AMT, which later became uniQure). In 2012 he was appointed CSO. During his 10 years at AMT/uniQure he was involved in the development of several gene therapy programs including Glybera for lipoprotein lipase deficiency. Glybera is the first gene therapy product approved in EU.
Harald holds a PhD degree from the Justus-Liebig University of Giessen (GER).
Harald has 20+ years of experience in the field of gene therapy. After his PhD on retroviruses, retroelements and cancer, he worked for 10 years at the German Primate Center on vaccines. During this time, he worked on a Polyomavirus-based gene delivery system which was transferred to Jenapharm GmbH for further development.
Harald joined Jenapharm GmbH in 2000. In 2002 he joined Berlex Biosciences (US) as Project Leader. In 2007, he became the Director of Research at Amsterdam Molecular Therapeutics (AMT, which later became uniQure). In 2012 he was appointed CSO. During his 10 years at AMT/uniQure he was involved in the development of several gene therapy programs including Glybera for lipoprotein lipase deficiency. Glybera is the first gene therapy product approved in EU.
Harald holds a PhD degree from the Justus-Liebig University of Giessen (GER).
Dr. Bernard Schneider – CSO and co-founder
Bernard is a Research and Teaching Associate at the Brain Mind Institute of EPFL. Since 2017, he is heading the Bertarelli Gene Therapy Platform, leading a team producing viral vectors and supporting the development of gene therapies for disorders of the central nervous system and sensory organs, including ALS. In 2006, he joined the Brain Mind Institute as senior scientist and later as a group leader in the team of Prof. Patrick Aebischer. Bernard has 16+ years of experience in Neurosciences, with a focus on translational research for the treatment of neurodegenerative disorders. He is the author of 100+ publications related to neurodegenerative diseases. He has worked on the development of AAV vectors adapted to gene therapy against familial forms of ALS, deafness and blindness. Bernard holds a PhD in Biomedical Sciences from the University of Lausanne (2001) and spent three years for postdoctoral research in Neurosciences at the University of Wisconsin in Madison, USA.
Bernard is a Research and Teaching Associate at the Brain Mind Institute of EPFL. Since 2017, he is heading the Bertarelli Gene Therapy Platform, leading a team producing viral vectors and supporting the development of gene therapies for disorders of the central nervous system and sensory organs, including ALS. In 2006, he joined the Brain Mind Institute as senior scientist and later as a group leader in the team of Prof. Patrick Aebischer. Bernard has 16+ years of experience in Neurosciences, with a focus on translational research for the treatment of neurodegenerative disorders. He is the author of 100+ publications related to neurodegenerative diseases. He has worked on the development of AAV vectors adapted to gene therapy against familial forms of ALS, deafness and blindness. Bernard holds a PhD in Biomedical Sciences from the University of Lausanne (2001) and spent three years for postdoctoral research in Neurosciences at the University of Wisconsin in Madison, USA.
Dr. Harald Petry - CEO and co-founder
Dr. Bernard Schneider – CSO and co-founder
Harald has 20+ years of experience in the field of gene therapy. After his PhD on retroviruses, retroelements and cancer, he worked for 10 years at the German Primate Center on vaccines. During this time, he worked on a Polyomavirus-based gene delivery system which was transferred to Jenapharm GmbH for further development.
Harald joined Jenapharm GmbH in 2000. In 2002 he joined Berlex Biosciences (US) as Project Leader. In 2007, he became the Director of Research at Amsterdam Molecular Therapeutics (AMT, which later became uniQure). In 2012 he was appointed CSO. During his 10 years at AMT/uniQure he was involved in the development of several gene therapy programs including Glybera for lipoprotein lipase deficiency. Glybera is the first gene therapy product approved in EU.
Harald holds a PhD degree from the Justus-Liebig University of Giessen (GER).
Harald joined Jenapharm GmbH in 2000. In 2002 he joined Berlex Biosciences (US) as Project Leader. In 2007, he became the Director of Research at Amsterdam Molecular Therapeutics (AMT, which later became uniQure). In 2012 he was appointed CSO. During his 10 years at AMT/uniQure he was involved in the development of several gene therapy programs including Glybera for lipoprotein lipase deficiency. Glybera is the first gene therapy product approved in EU.
Harald holds a PhD degree from the Justus-Liebig University of Giessen (GER).
Bernard is a Research and Teaching Associate at the Brain Mind Institute of EPFL. Since 2017, he is heading the Bertarelli Gene Therapy Platform, leading a team producing viral vectors and supporting the development of gene therapies for disorders of the central nervous system and sensory organs, including ALS. In 2006, he joined the Brain Mind Institute as senior scientist and later as a group leader in the team of Prof. Patrick Aebischer. Bernard has 16+ years of experience in Neurosciences, with a focus on translational research for the treatment of neurodegenerative disorders. He is the author of 100+ publications related to neurodegenerative diseases. He has worked on the development of AAV vectors adapted to gene therapy against familial forms of ALS, deafness and blindness. Bernard holds a PhD in Biomedical Sciences from the University of Lausanne (2001) and spent three years for postdoctoral research in Neurosciences at the University of Wisconsin in Madison, USA.
Management Team